var data={"title":"Nitroprusside: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitroprusside: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6663?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">see &quot;Nitroprusside: Drug information&quot;</a> and <a href=\"topic.htm?path=nitroprusside-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitroprusside: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709173\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nitropress: After reconstitution, nitroprusside is not suitable for direct injection. The reconstituted solution must be further diluted in dextrose 5% injection before infusion.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypotension:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Use only when available equipment and personnel allow blood pressure to be continuously monitored.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cyanide toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Except when used briefly or at low (less than 2 mcg/kg/min) infusion rates, nitroprusside injection gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels. The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rates should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, terminate administration immediately. Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nipride RTU;</li>\n      <li>Nitropress</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12817125\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nipride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054446\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675229\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension, acute:</b> Limited data available: Continuous IV infusion: Initial: 0.5 mcg/kg/minute; titrate to effect; maximum infusion rate: 10 mcg/kg/minute; this dosing has been recommended by experts for neonates with hypertensive urgency/emergency (Flynn 2000). Use in neonates has been described in several retrospective reports and case series; most recent and majority of patient experience is during cardiac surgery requiring cardiopulmonary bypass and postoperatively for afterload reduction; initial doses as low as 0.2 mcg/kg/minute and titrated to effect up to 8 mcg/kg/minute have been reported (Benitz 1985; Cachat 2004; Furck 2010; Kiran 2006; Motta 1995; Williams 1994); however, doses &ge;1.8 mcg/kg/minute have been associated with increased cyanide concentration in pediatric postoperative cardiac surgery patients, including neonates (Moffett 2008); reported duration of therapy was typically &lt;6 to 7 days; some experts recommend monitoring cyanide concentrations with prolonged use (eg, &gt;72 hours) (NHBPEP 2004). Use for 6 days at a maximum dose of 2.5 mcg/kg/minute produced profound lactic acidosis in a term neonate with congenital heart rate (Meyer 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46977912\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">see &quot;Nitroprusside: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension, acute including hypertensive crisis:</b> Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.3 to 0.5 mcg/kg/minute, titrate every 5 minutes to desired effect; usual dose: 3 to 4 mcg/kg/minute; maximum dose: 10 mcg/kg/minute (Chandar 2012; Hegenbarth 2008; NHBPEP 2004; Park 2014); increased infusion rates are correlated with increased cyanide concentrations (Hammer 2015); a study in pediatric postoperative cardiac surgery patients found patients with rates &ge;1.8 mcg/kg/minute had increased cyanide concentrations (Moffett 2008); monitor cyanide levels with prolonged use (eg, &gt;72 hours) (NHBPEP 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac output maintenance/stabilization, postresuscitation</b> (PALS [Kleinman 2010]): Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 to 1 mcg/kg/minute, titrate to desired effect; maximum dose: 8 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute hypertension:</b> Continuous IV infusion: Initial: 0.3 to 0.5 mcg/kg/minute; may be titrated by 0.5 mcg/kg/minute every few minutes to achieve desired hemodynamic effect (Rhoney 2009); maximum rate: 10 mcg/kg/minute (for a maximum of 10 minutes). To avoid toxicity, some recommend a maximum dose of 2 mcg/kg/minute (Marik 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute decompensated heart failure:</b> Continuous IV infusion: Initial: 5 to 10 <b>mcg/minute</b>; may be titrated rapidly (eg, up to every 5 minutes) to achieve desired hemodynamic effect; usual dosage range: 5 to 300 <b>mcg/minute</b>. Doses &gt;400 <b>mcg/minute</b> are not recommended due to minimal added benefit and increased risk for thiocyanate toxicity (HFSA [Lindenfeld 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: Use in patients with renal impairment may lead to the accumulation of thiocyanate and subsequent toxicity; limit use and monitor thiocyanate blood concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Limit mean infusion rate to &lt;3 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anuric patients: Limit mean infusion rate to 1 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; due to the risk of cyanide toxicity, use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202177\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitropress: 25 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nipride RTU: 10 mg/50 mL in NaCl 0.9% (50 mL); 50 mg/100 mL in NaCl 0.9% (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202162\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054451\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer as continuous IV infusion via infusion pump. Solution should be protected from light, but not necessary to wrap administration set or IV tubing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concentrated solution (25 mg/mL): Not for direct injection; must dilute prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ready to use (0.5 mg/mL): No further dilution required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473002\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 100 <b>mcg</b>/mL <b>or</b> 200 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202193\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Nitropress, Nipride RTU vial: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light; recommended to store in carton until used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stability of parenteral admixture in D5W, LR, or NS at room temperature (25&deg;C) and at refrigeration temperature (4&deg;C) is 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054450\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of hypertensive crises (FDA approved in pediatric patients [age not specified] and adults); used for controlled hypotension to reduce bleeding during surgery (FDA approved in pediatric patients [age not specified] and adults); treatment of acute heart failure (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroprusside may be confused with nitroglycerin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202235\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, ECG changes, flushing, palpitations, severe hypotension, substernal pain, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apprehension, dizziness, headache, increased intracranial pressure, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, localized erythematous streaking, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, intestinal obstruction, nausea, retching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased platelet aggregation, methemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Irritation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle twitching</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202185\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); to produce controlled hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) requiring emergency surgery; acute heart failure associated with reduced systemic vascular resistance (eg, septic shock); congenital (Leber's) optic atrophy or tobacco amblyopia; concomitant use with sildenafil, tadalafil, vardenafil, or riociguat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindication (not in US labeling): Hypersensitivity to nitroprusside or any component of the formulation; uncorrected anemia or hypovolemia; hepatic disease; severe renal disease; disease states associated with vitamin B<sub>12</sub> deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202166\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cyanide toxicity: <b>[US Boxed Warning]: Except when used briefly or at low (&lt;2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled by the maximum rate (ie, 10 mcg/kg/minute) after 10 minutes, discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration; however, clinicians should note that these indicators may not always reliably indicate cyanide toxicity. </b> Patients at risk of cyanide toxicity include those who are malnourished, have hepatic impairment, or those undergoing cardiopulmonary bypass, or therapeutic hypothermia (Rindone 1992). Discontinue use of nitroprusside if signs and/or symptoms of cyanide toxicity (eg, metabolic acidosis, decreased oxygen saturation, bradycardia, confusion, convulsions) occur. Although not routinely done, sodium thiosulfate has been co-administered with nitroprusside using a 10:1 ratio of sodium thiosulfate to nitroprusside when higher doses of nitroprusside are used (eg, 4 to 10 mcg/kg/minute) for extended periods of time in order to prevent cyanide toxicity (Shulz 2010; Varon 2008); thiocyanate toxicity may still occur with this approach (Rindone 1992). The use of other agents (eg, clevidipine, labetalol, nicardipine) should be considered if blood pressure is not controlled with nitroprusside.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: <b>[US Boxed Warning]: Excessive hypotension resulting in compromised perfusion of vital organs may occur; continuous blood pressure monitoring by experienced personnel is required. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Use may elevate intracranial pressure; in patients whose intracranial pressure is already elevated, use only with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methemoglobinemia: Nitroprusside can cause a dose-dependent conversion of hemoglobin to methemoglobin. Methemoglobinemia should be suspected in any patient receiving &gt;10 mg/kg of nitroprusside and exhibiting signs of impaired oxygen delivery despite adequate cardiac output and arterial pO<sub>2</sub>. Symptomatic patients, regardless of methemoglobin level should be treated with methylene blue (first-line). Treatment is suggested if level is &ge;30% even if asymptomatic unless patient has a preexisting condition (eg, coronary artery disease) and are incapable of tolerating reductions in oxygen carrying capacity then treatment is suggested if level reaches 10% (Cortazzo 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thiocyanate toxicity: Can occur in patients with renal impairment or those on prolonged infusions (ie, &gt;3 mcg/kg/minute for &gt;72 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing anemia prior to use when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing hypovolemia prior to use when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use caution in patients with acute myocardial infarction because of hemodynamic effects and possible coronary steal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with extreme caution in patients with renal impairment; use the lowest end of the dosage range; monitor thiocyanate concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: Nitropress: <b>[US Boxed Warning]: Solution must be further diluted with 5% dextrose in water. Do not administer by direct injection.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299769\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202171\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12648&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Nitroprusside.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202173\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13263869\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels.  However, information related to use in pregnancy is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054445\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate; monitor for cyanide and thiocyanate toxicity; monitor venous oxygen saturation; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (&gt;3 days) or dose &ge;4 mcg/kg/minute or patient has renal dysfunction; monitor cyanide blood levels in patients with decreased hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054449\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiocyanate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic: 35 to 100 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fatal: &gt;200 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal &lt;0.2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal (smoker): &lt;0.4 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic: &gt;2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Potentially lethal: &gt;3 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202165\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202184\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Hypotensive effect: &lt;2 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Hypotensive effect: 1-10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nitroprusside combines with hemoglobin to produce cyanide and cyanmethemoglobin. Cyanide detoxification occurs via rhodanase-mediated conversion of cyanide to thiocyanate; rhodanase couples cyanide molecules to sulfane sulfur groups from a sulfur donor (eg, thiosulfate, cystine, cysteine). This process has limited capacity and may become overwhelmed with large exposures once sulfur donor supplies are exhausted resulting in toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Nitroprusside, circulatory: ~2 minutes; Thiocyanate, elimination: ~3 days (may be doubled or tripled in renal failure) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as thiocyanate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323524\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nipride RTU Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/50 mL 0.9% (50 mL): $48.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/100 mL 0.9% (100 mL): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitropress Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (2 mL): $360.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroprusside Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (2 mL): $330.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202187\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Doketrol (AR);</li>\n      <li>Naniprus (PL);</li>\n      <li>Nipride (BE, CH, FR, GB, IE, LU, NL, QA, SA);</li>\n      <li>Niprusodio (UY);</li>\n      <li>Nipruss (DE, EG, JO, LU);</li>\n      <li>Nitan (MX);</li>\n      <li>Nitriate (FR, VN);</li>\n      <li>Nitrocef (BD);</li>\n      <li>Nitroprus (BR);</li>\n      <li>Nitroprusiato de sodio (PE, PY, VE);</li>\n      <li>Nitroprusiato de sodio-ecar (CO);</li>\n      <li>Nitroprussiat Fides (ES);</li>\n      <li>Sodio Nitroprussiato (IT);</li>\n      <li>Sodium Nitroprusside (GB);</li>\n      <li>Sodium Nitroprusside BP (AU);</li>\n      <li>Sonide (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Benitz WE, Malachowski N, Cohen RS, et al, &quot;Use of Sodium Nitroprusside in Neonates: Efficacy and Safety,&quot; <i>J Pediatr</i>, 1985, 106(1):102-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/3917495/pubmed\" target=\"_blank\" id=\"3917495\">3917495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cachat F, Bogaru A, Micheli JL, et al, &quot;Severe Hypertension and Massive Proteinuria in a Newborn With Renal Artery Stenosis,&quot; <i>Pediatr Nephrol</i>, 2004, 19(5):544-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/14986083/pubmed\" target=\"_blank\" id=\"14986083\">14986083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cachat F and Guignard JP, &quot;Reply to the Letter From C. von Schnakenburg and M. Kr&uuml;ger,&quot; <i>Pediatr Nephrol</i>, 2004, 19:1308-09.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandar J, Zilleruelo G. Hypertensive crisis in children. <i>Pediatr Nephrol</i>. 2012;27( 5 ):741-751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/21773822/pubmed\" target=\"_blank\" id=\"21773822\">21773822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT. Neonatal hypertension: diagnosis and management. <i>Pediatr Nephrol</i>. 2000;14(4):332-341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/21773822/pubmed\" target=\"_blank\" id=\"21773822\">21773822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furck AK, Hansen JH, Uebing A, et al, &quot;The Impact of Afterload Reduction on the Early Postoperative Course After the Norwood Operation - A 12-year Single-Centre Experience,&quot; <i>Eur J Cardiothorac Surg</i>, 2010, 37(2):289-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/19800251/pubmed\" target=\"_blank\" id=\"19800251\">19800251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hammer GB, Lewandowski A, Drover DR, et al. Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. <i>Pediatr Crit Care Med</i>. 2015;16(5):397-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/25715047/pubmed\" target=\"_blank\" id=\"25715047\">25715047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiran U, Zuber K, and Kakani M, &quot;Combination of Low-Dose Phenoxybenzamine and Sodium Nitroprusside in Children Undergoing Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 2006, 20(2):291-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/16616682/pubmed\" target=\"_blank\" id=\"16616682\">16616682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive heart failure practice guideline. <i>J Card Fail</i>. 2010;16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Varon J. Hypertensive crises: challenges and management. <i>Chest</i>. 2007;131(6):1949-1962.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer S, Baghai A, Sailer NL, et al, &quot;Lactic Acidosis Caused by Sodium Nitroprusside in a Newborn With Congenital Heart Disease,&quot; <i>Eur J Pediatr</i>, 2005, 164(4):253-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/15666157/pubmed\" target=\"_blank\" id=\"15666157\">15666157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffett BS and Price JF, &quot;Evaluation of Sodium Nitroprusside Toxicity in Pediatric Cardiac Surgical Patients,&quot; <i>Ann Pharmacother</i>, 2008, 42(11):1600-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/18957627/pubmed\" target=\"_blank\" id=\"18957627\">18957627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motta P, Mossad E, Toscana D, et al, &quot;Comparison of Phenoxybenzamine to Sodium Nitroprusside in Infants Undergoing Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 2005, 19(1):54-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/15747270/pubmed\" target=\"_blank\" id=\"15747270\">15747270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations.<i> Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2 Suppl 4th Report):555-576.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nipride RTU (nitroprusside) [prescribing information]. Lenoir, NC: Exela Pharma Sciences, LLC; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitropress injection (nitroprusside) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pramar Y, Das Gupta V, Gardner SN, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. <i>J Clin Pharm Ther</i>. 1991;16(3):203-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/1907977 /pubmed\" target=\"_blank\" id=\"1907977 \">1907977 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. <i>Am J Health Syst Pharm</i>. 2009;66(15):1343-1352.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/1907977 /pubmed\" target=\"_blank\" id=\"1907977 \">1907977 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management. <i>Ann Pharmacother</i>. 1992;26:515-519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/1533553/pubmed\" target=\"_blank\" id=\"1533553\">1533553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulz LT, Elder EJ, Jones KJ, et al. Stability of Sodium nitroprusside and sodium thiosulfate 1:10 intravenous admixture. <i>Hosp Pharm</i>. 2010;45(10):779-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/21625332/pubmed\" target=\"_blank\" id=\"21625332\">21625332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varon J. Treatment of acute severe hypertension. <i>Drugs</i>. 2008;68(3):283-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/18257607/pubmed\" target=\"_blank\" id=\"18257607\">18257607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Schnakenburg C and Kr&uuml;ger M, &quot;Note of Caution for the Use of Sodium Nitroprusside in Neonatal Hypertension,&quot; <i>Pediatr Nephrol</i>, 2004, 19(11):1307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-pediatric-drug-information/abstract-text/15338387/pubmed\" target=\"_blank\" id=\"15338387\">15338387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams RS, Mickell JJ, Young ES, et al, &quot;Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 1994, 8(6):658-62.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12648 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709173\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12817125\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054446\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675229\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F46977912\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202177\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202162\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054451\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473002\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F202193\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054450\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202235\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202185\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202166\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299769\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202171\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202173\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13263869\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054445\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1054449\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202165\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202184\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323524\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202187\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12648|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">Nitroprusside: Drug information</a></li><li><a href=\"topic.htm?path=nitroprusside-patient-drug-information\" class=\"drug drug_patient\">Nitroprusside: Patient drug information</a></li></ul></div></div>","javascript":null}